Status:
COMPLETED
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
Lead Sponsor:
Amgen
Conditions:
Anemia
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladde...
Detailed Description
Before enrolling participants, each country was assigned to either cohort 1 (patients receiving only darbepoetin alfa) or cohort 2 (patients receiving any ESA). Cohort 2 was assigned only to those cou...
Eligibility Criteria
Inclusion
- Diagnosed with breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal, pancreatic, esophageal or gastric cancer
- Expected to receive at least 8 additional weeks of a given regimen of myelosuppressive chemotherapy after enrolment
- Starting treatment with either darbepoetin alfa (in Cohort 1 countries) or any ESA (in Cohort 2 countries) as per European Summary of Product Characteristics (SPC) for symptomatic anaemia.
Exclusion
- Received any ESA treatment or Red Blood Cell (RBC) transfusion within 28 days prior to enrolment
- Known primary benign or malignant haematologic disorder which can cause anaemia
- Known hypersensitivity to ESAs
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1262 Patients enrolled
Trial Details
Trial ID
NCT01444456
Start Date
October 1 2011
Last Update
March 20 2017
Active Locations (117)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Graz, Austria, 8042
2
Research Site
Innsbruck, Austria, 6020
3
Research Site
Sankt Pölten, Austria, 3100
4
Research Site
Vienna, Austria, 1090